Prestorage filtration of blood components for patients who are chronically transfusion dependent

Beck S, Stevens A
Record ID 31998008871
English
Authors' objectives:

Filtration of blood components which are to be transfused to chronically transfusion dependent patients reduces the number of white blood cells in the component, to a level at which they are unlikely to cause harmful sequelae. Leucodepletion prestorage, rather than at the bedside, is proposed to be more effective. The author aims to investigate how reliable this proposal is.

Authors' results and conclusions: The trials which consider prestorage leucodepletion have demonstrated that it is an effective method. Adverse consequences are reduced when prestorage rather than standard products are used. However a further conclusion these studies identify is that prestorage leucodepletion does not have conclusive benefits for patients with a positive risk history.
Authors' recomendations: Prestorage filtration is theoretically preferable to no leucodepletion or bedside filtration, that is, it is expected to be more effective in reducing the incidence of FTRs, alloimmunization and refractoriness. However, the author concludes that the quality of the evidence is insufficient to quantify the benefits.
Authors' methods: Review
Details
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Blood Preservation
  • Blood Transfusion
  • Filtration
  • Leukocytes
  • Cell Separation
  • Hemofiltration
Contact
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.